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Hypertension (HTN) and smoking are estab-
lished risk factors for cardiovascular disease 
(U.S. Department of Health and Human 
Services 2000), the leading cause of death 
worldwide (World Health Organization 2009). 
The etiology of essential HTN, however, is 
unknown (Carretero and Oparil 2000), but 
cadmium exposure has been inconsistently 
associated with blood pressure (BP). For 
example, Järup and Akesson (2009) recently 
reviewed the literature on cadmium and health 
effects and identified single-study–reported 
associations between cadmium and cardio-
vascular effects other than HTN. More than 
10 years earlier, Nakagawa and Nishijo (1996) 
conducted a review of cadmium exposure and 
HTN and found that, although general popu-
lation studies had reported positive associations 
of blood cadmium (BCd) and urinary cad-
mium (UCd) with BP, inverse associations had 
been reported in studies of residents or workers 
with known environmental or occupational 
exposures. Nakagawa and Nishijo (1996) 
interpreted these differences as an effect of low 
versus high exposures to cadmium, identified 
exposure misclassification as a limitation of 
studies conducted before the 1970s when cad-
mium measurements were semiquantitative, 
and also noted failure to account for the influ-
ence of smoking as a concern. Smoking is asso-
ciated with increased cadmium levels because 
cigarettes contain cadmium taken up by the 
tobacco plant [Agency for Toxic Substances 
and Disease Registry (ATSDR) 2008]. Smokers 
have approximately twice the cadmium body 
burden of nonsmokers (ATSDR 2008). In 
nonsmokers, however, food is the primary 
source of exposure (ATSDR 2008). Nakagawa 
and Nishijo (1996) concluded that additional 
studies that control for smoking are needed, 
and several new studies that separated smokers 
from nonsmokers have been published since 
their review.
Since 1989, advancements in the technol-
ogy to analyze BCd and UCd have improved 
the reliability of human exposure measures 
(Tsalev 1995); however, the use of these bio-
markers has been inconsistent across epide-
miological studies of HTN and BP. UCd is 
a biomarker for lifetime cadmium exposure 
among people with lower, nonoccupational 
exposures because, in the absence of episodes 
of high-level exposure, cadmium-binding 
sites, primarily in the kidney and liver, are not 
saturated, and UCd increases in proportion 
to the amount of cadmium stored in the body 
(Dillon and Ho 1991). UCd, however, can 
also reflect recent exposure (ATSDR 2008). 
BCd is a biomarker of recent exposure, with 
a half-life of 3–4 months, and is considered 
a biomarker for longer term exposure that 
reflects accumulation in the blood from body 
stores over a 10-year period (Järup et al. 
1998). A greater percentage of inhaled rather 
than ingested cadmium is absorbed into the 
bloodstream (Järup et al. 1983, 1998). Thus, 
UCd and BCd levels may provide different 
information regarding the timing and source 
of exposure among smokers and nonsmokers.
The objectives of our systematic review and 
meta-analysis were to update and reevaluate the 
evidence regarding the relationships of BCd 
and UCd and BP and HTN and to discern the 
extent to which previously reported correlations 
may be associated with   nonsmoking-related 
exposures, as indicated by BCd and UCd 
  estimated effects in never-smokers.
Materials and Methods
We conducted an electronic search using 
PubMed (National Library of Medicine; 
http://www.ncbi.nlm.nih.gov/sites/entrez) to 
locate all relevant articles that address BCd 
and/or UCd and BP in humans and smoking 
status. We used the following a priori inclu-
sion criteria: UCd and BCd levels and systolic 
BP (SBP), diastolic BP (DBP), or HTN; the 
study population was not restricted to a spe-
cific disease, condition, or otherwise unique 
subset. We adjusted the statistical evaluation 
for smoking status, age, and sex; the dif-
ference in mean cadmium values between 
HTN cases and normotensive controls and/or 
associations between cadmium levels and BP 
and/or HTN were evaluated for statistical 
significance. We used cross-sectional, case– 
control, or cohort study design and conducted 
original analyses. To assess general population 
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Ba c k g r o u n d: Cadmium exposure has been inconsistently related to blood pressure.
oBjectives: We updated and reevaluated the evidence regarding the relationships of blood cadmium 
(BCd) and urine cadmium (UCd) with blood pressure (BP) and hypertension (HTN) in nonoccu-
pationally exposed populations.
da t a s o u r c e s a n d e x t r a c t i o n: We searched PubMed and Web of Science for articles on BCd or 
UCd and BP or HTN in nonoccupationally exposed populations and extracted information from 
studies that provided sufficient data on population, smoking status, exposure, outcomes, and design.
da t a synthesis: Twelve articles met inclusion criteria: eight provided data adequate for compari-
son, and five reported enough data for meta-analysis. Individual studies reported significant positive 
associations between BCd and systolic BP (SBP) among nonsmoking women [β = 3.14 mmHg per 
1 μg/L untransformed BCd; 95% confidence interval (CI), 0.14–6.14] and among premenopausal 
women (β = 4.83 mmHg per 1 nmol/L log-transformed BCd; 95% CI, 0.17–9.49), and between 
BCd and diastolic BP (DBP) among women (β = 1.78 mmHg comparing BCd in the 90th and 
10th percentiles; 95% CI, 0.64–2.92) and among premenopausal women (β = 3.84 mmHg per 
1 nmol/L log-transformed BCd; 95% CI, 0.86–6.82). Three meta-analyses, each of three stud-
ies, showed positive associations between BCd and SBP (p = 0.006) and DBP (p < 0.001) among 
women, with minimal heterogeneity (I2 = 3%), and a significant inverse association between UCd 
and HTN among men and women, with substantial heterogeneity (I2 = 80%).
co n c l u s i o n: Our results suggest a positive association between BCd and BP among women; the 
results, however, are inconclusive because of the limited number of representative population-based 
studies of never-smokers. Associations between UCd and HTN suggest inverse relationships, but 
inconsistent outcome definitions limit interpretation. We believe a longitudinal study is merited.
key w o r d s : blood, blood pressure, cadmium, hypertension, meta-analysis, smoking, systematic 
review, urine. Environ Health Perspect 118:1676–1684 (2010).  doi:10.1289/ehp.1002077 [Online 
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exposures, we excluded studies that specifi-
cally assessed occupationally exposed popula-
tions. We used the following medical subject 
heading (MeSH) terms—population, inter-
vention and exposure, comparison, outcome, 
study design (Liberati et al. 2009): a) popula-
tion: human AND adult AND NOT occu-
pational exposure; b) biomarker of exposure: 
cadmium and administration and dosage, 
cadmiumand adverse effects or cadmium and 
blood or cadmium and urine or cadmium and 
toxicity; c) comparisons: smoking status and 
sex (no MeSH terms specified); d) outcomes: 
BP or BP monitoring, ambulatory, or HTN; 
e) study designs: cross-sectional, case–control, 
cohort. We excluded studies that were limited 
to occupationally exposed populations (no 
MeSH terms specified).
Additionally, we conducted an electronic 
“bottom-up” search in the Web of Science 
(Thomson Reuters, New York, NY) to find 
articles that cite results of the PubMed litera-
ture search. Studies were limited to those pub-
lished from 1989 to 2009 based on evidence 
of reliability of the technology to measure and 
analyze BCd and UCd (Tsalev 1995).
We developed a combined approach to 
weight the evidence of individual studies [see 
Supplemental Material, Table 1 (doi:10.1289/
ehp.1002077)]. Study characteristics that 
merited higher weight-of-evidence (WOE) 
grades included separation by smoking sta-
tus (i.e., either results were presented sepa-
rately for smokers and never-smokers, or the 
population was restricted to never-smokers or 
nonsmokers), control for anti-HTN medica-
tion use, ambulatory or multiple BP meas-
ure  ments, analysis of both BCd and UCd 
biomarkers, or samples that represent general 
populations. In Table 1, the footnote gives the 
WOE codes that were used to qualitatively 
guide interpretation of the findings of the 
systematic review.
Findings of studies that reported multi-
variate-adjusted measures of association and 
95% confidence intervals (CIs), and/or stan-
dard errors (SEs) or t-values, are presented 
in Figures 1–5. In the absence of reported 
CIs (Pizent et al. 2001; Satarug et al. 2005; 
Staessen et al. 2000; Whittemore et al. 1991), 
we calculated 95% CIs as 1.96 × SE and thus 
represent approximate intervals. Unreported 
SEs (Satarug et al. 2005) were calculated 
by dividing the reported coefficient by the 
reported t-value (Rosner 2006). For results 
presented in the original article in graph for-
mat only (i.e., findings for never-smokers 
reported by Whittemore et al. 1991), val-
ues for estimates and 95% CIs were visually 
approximated. Mean BCd and UCd values 
originally reported in nanomoles per liter 
were converted to micrograms per liter by 
dividing by 8.897, and creatinine-adjusted 
UCd values originally reported as nanomoles 
per millimole creatinine were converted to 
micrograms per gram creatinine by dividing 
by 1.006 (Tellez-Plaza 2008). Interpretations 
of statistical significance are based on an alpha 
level ≤ 0.05.
Because two studies are a suggested mini-
mum requirement for a systematic review to 
include a meta-analysis (Littell et al. 2008), 
we required at least three studies with compa-
rable exposure and outcome measures. Meta-
analysis was conducted using random effects 
models and inverse variance methods to 
weight effect estimates. Random effects mod-
els were used to account for variation among 
the studies (Littell et al. 2008). Inverse vari-
ance methods were used to give greater weight 
to studies characterized by greater precision, 
that is, relatively narrow CIs (Littell et al. 
2008). Meta-analysis was performed using 
Review Manager 5.0 (RevMan; Cochrane 
Collaboration, Copenhagen, Denmark, 
http://ims.cochrane.org/revman).
Results
Literature search. Electronic search results 
yielded a total of 33 citations; of these only 12 
met the inclusion criteria [see Supplemental 
Material, Table 2 (doi:10.1289/ehp.1002077) 
for citations of excluded articles and the rea-
sons for exclusion].
Large representative population-based 
samples, stratified by smoking status. Tellez-
Plaza et al. (2008) analyzed data from the 
1999–2004 National Health and Nutrition 
Examination Survey (NHANES; n = 10,991), 
and Whittemore et al. (1991) analyzed 
data from the 1976–1988 NHANES II 
(n = 960); both were cross-sectional studies 
(Table 1). Tellez-Plaza et al. (2008) defined 
HTN as mean SBP ≥ 140 mmHg, a mean 
DBP ≥ 90 mmHg, a self-reported physician 
diagnosis, or the use of medication for HTN; 
Whittemore et al. (1991) defined HTN by 
anti-HTN drug use only. Exposure measures 
included spot urine samples for both studies; 
however, Tellez-Plaza et al. (2008) used multi-
variate adjustment for creatinine to adjust for 
urine dilution effects, whereas Whittemore 
et al. (1991) directly adjusted UCd measure-
ments for specific gravity. Tellez-Plaza et al. 
(2008) also estimated associations with BCd. 
Whittemore et al. (1991) estimated associa-
tions with continuous, untransformed UCd 
measures, and Tellez-Plaza et al. (2008) esti-
mated associations for cadmium quartiles 
(relative to the lowest quartile) and for cad-
mium levels at or above the 90th percentile 
compared with cadmium at or below the 10th 
percentile, in addition to estimating associa-
tions with log-transformed continuous bio-
marker measures. The NHANES II database 
used by Whittemore et al. (1991) lacked 
appropriate sample weights for the subsample 
with cadmium measurements. Thus, p-values 
and CIs were calculated based on the assump-
tion that this subsample is a simple random 
sample of the U.S. population. Tellez-Plaza 
et al. (2008) adjusted for HTN medica-
tion use in multivariate analyses but did not 
exclude treated HTN subjects from the analy-
sis of never-smokers; in contrast, Whittemore 
et al. (1991) conducted two sets of analy-
ses: One included all subjects and statistically 
adjusted for current hypertensive medication 
use, and the second set excluded subjects who 
had been treated for HTN.
Small studies, limited to   nonsmokers. 
These four studies ranged in sample size 
from 53–267 subjects. Outcome measures 
included continuous SBP and DBP (Pizent 
et al. 2001; Satarug et al. 2005); dichotomous 
SBP and/or DBP, that is, SBP > 140 mmHg 
and/or DBP > 90 mmHg (Vivoli et al. 1989); 
mean SBP (Satarug et al. 2005); and mean 
arterial pressure (Lin et al. 1995). Exposure 
measures included 3-hr log-transformed 
UCd (Satarug et al. 2005), mean creatinine-
adjusted spot UCd (Vivoli et al. 1989), and 
untransformed BCd (Lin et al. 1995; Pizent 
et al. 2001). The three cross-sectional studies 
were limited to nonsmokers (Lin et al. 1995; 
Pizent et al. 2001; Satarug et al. 2005), and 
the one case–control study matched cases 
and controls for smoking status (Vivoli et al. 
1989). Treated HTN subjects were excluded 
from all four studies. Study populations 
were urban (Satarug et al. 2005) and rural 
(Pizent et al. 2001), clinic recruited (Lin et al. 
1995), and occupation specific (Vivoli et al. 
1989). Findings from Lin et al. (1995) are 
not depicted in graph format because the out-
come measure (i.e., mean arterial BP) was 
not comparable with those of the other stud-
ies. Additionally, findings from Vivoli et al. 
(1989) are not plotted because this study 
analyzed the difference in mean cadmium 
between cases and controls and did not report 
comparable measures of association.
Large studies, not limited to nonsmokers. 
These three cross-sectional studies used the fol-
lowing number of subjects: 2,853 (Kurihara 
et al. 2004), 1,902 (Eum et al. 2008), and 
1,223 (Menditto et al. 1998). Outcome 
meas  ures included categorical measures of 
HTN, that is, SBP ≥ 140 mmHg and/or 
DBP > 90 mmHg or taking anti-HTN drugs 
(Kurihara et al. 2004) or SBP ≥ 140 mmHg 
or DBP ≥ 90 mmHg or self-reported HTN 
in medical examination (Eum et al. 2008); 
continuous SBP and DBP (Eum et al. 2008; 
Menditto et al. 1998); and mean BP, that is, 
DBP + pulse pressure ÷ 3 (Eum et al. 2008) 
and DBP + 1/3 × (SBP – DBP) (Menditto 
et al. 1998). Exposure measures included 
BCd tertiles (0.18–1.28 μg/L, 1.29–1.86 
μg/L, 1.87–5.52 μg/L (Eum et al. 2008); 
84% upper cutoff dichotomized BCd and 
UCd, that is, geometric means × geometric Gallagher and Meliker
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Table 1. Study characteristics, key findings, and WOE codes.
Study population
Exposure 
measure Covariates Outcome measure Key findingsa
Study design/ 
WOE codesb Reference
Large representative population-based samples, with smoking-stratified findings
U.S. men and women ≥ 20 years 
of age; n = 10,991; mean BCd, 
0.42 μg/L; UCd, 0.28 μg/L
BCd, spot 
UCd without 
direct dilution 
adjustment
Age, sex, race, education, 
cotinine, alcohol, BMI, 
menopause, anti-HTN 
drug use, blood lead, 
and urinary creatinine 
for UCd
HTN = mean SBP 
≥ 140 mmHg, mean 
DBP ≥ 90 mmHg; 
self-reported 
physician diagnosis, 
or drug use; SBP, 
DBP, 3–4 measures
Never-smokers:
BCd + SBP
BCd + DBP
BCd o HTN
UCd – HTN
Cross-sectional 
(NHANES 
1999–2004), 
cadmium-weighted 
sample:
1. A
2. A
3. A/B
4. B
Tellez-Plaza 
et al. 2008
U.S. men and women 20–74 years 
of age; mean UCd: men, 1.1 μg/L; 
women, 1.3 μg/L; n = 960
Spot UCd, 
adjusted for 
specific gravity
Age, sex, race, Quetelet’s 
index, family history 
HTN, and anti-HTN drug 
use; never-smokers 
exclude HTN drug use
HTN = anti-HTN drug 
use; SBP, DBP, three 
measures
Never-smokers:
UCd o SBP
UCd o DBP
UCd o HTN
Cross-sectional 
(NHANES II 
1978–1979), cadmium-
unweighted sample:
1. B
2. A/B
3. A
4. B
Whittemore 
et al. 1991
Small studies, limited to nonsmokers
Adults 16–60 years of age, near 
Bangkok, Thailand, no occupational 
exposures; n = 100 women and 53 men 
who were never-smokers; UCd mean: 
women, 3.5 nM/3; men, 2.7 nM/3
3-hr UCd Age, BMI, urine lead; 
excluded subjects on 
anti-HTN drugs or any 
medication on a regular 
basis
SBP, DBP, MBP Never-smokers:
Men, UCd + SBP
Women, UCd o SBP
Cross-sectional:
1. B
2. B
3. A
4. C
Satarug 
et al. 2005
Never-smoking women 31–77 years 
of age, from routine and HTN clinics, 
Taiwan, near cadmium-polluted 
area; mean BCd: no HTN (n = 24), 
0.88 μg/L; untreated essential HTN 
(n = 24), 1.69 μg/L; nonessential HTN 
(n = 10), 0.92 μg/L
BCd, 24-hr UCd, 
creatinine 
adjusted
Age, BMI;
excluded smokers 
and occupational 
exposure history, 
proteinuria, hematuria, 
low creatinine clearance
MBP, averaged from 
three different visits 
on three different 
days
BCd + MBP
UCd + MBP
Cross-sectional:
1. B
2. B
3. A
4. C
Lin et al. 
1995
“Peasant” women 40–85 years of age 
from rural Croatia, all nonsmokers 
(included former smokers); n = 267; 
median BCd, 0.6 μg/L
BCd Area of residence (high vs. 
low calcium intake), age, 
alcohol, BMI, serum lead; 
excluded subjects on 
drugs that could affect BP
SBP, DBP BCd + SBP
BCd + DBP
Cross-sectional:
1. B
2. B
3. A/B
4. C
Pizent et al. 
2001
Male bankers from Modena, Italy; 
mean age, 37–38 years; epide-
miological screening: BCd mean 
hypertensive and normotensive, 
0.58/0.44 μg/L; UCd (creatinine 
adjusted) mean hypertensive 
andnormotensive, 1.36/1.23 μg/g; 
n = 63 HTN and 63 non-HTN
BCd; spot UCd, 
creatinine 
adjusted
Matched for age, smoking, 
anthropometrics, work 
conditions; excluded 
taking drugs for HTN
SBP > 140 and/or DBP 
> 90; 2 readings
Mean BCd: cases, 
0.41 μg/L; controls, 
0.25 μg/L (p < 0.01); 
no significant 
difference in UCd 
between cases and 
controls
Case–control:
1. A
2. B
3. A
4. C
Vivoli et al. 
1989
Large studies, not limited to nonsmokers
Nonoccupationally exposed, 
≥ 50 years of age, from three 
“unpolluted” rural areas, Japan; 
n = 1,140 men and 1,713 women; 
geometric mean BCd: men, 2.2 μg/L; 
women, 2.3 μg/L; geometric mean 
UCd (creatinine adjusted): men, 
1.8 μg/g; women, 2.4 μg/g
BCd; spot UCd, 
creatinine 
adjusted
Age, smoking (nonsmoker, 
including ex-smoker, 
and current smokers) 
alcohol intake, serum 
creatinine; BMI, beta-2 
microglobulin
HTN = SBP > 140 or 
DBP > 90 or taking 
anti-HTN drugs
BCd o HTN
UCd – HTN
Cross-sectional:
1. B
2. C
3. B/C
4. C
Kurihara 
et al. 2004
Korean men and women ≥ 20 years of 
age; n = 958 men and 944 women; 
mean BCd, 1.67 μg/L
BCd; T1, 0.18–
1.28 μg/L (ref); 
T2, 1.29–
1.86 μg/L; 
T3, 1.87–
5.52 μg/L
Age, sex, education, 
smoker (never, ex, 
current), alcohol intake, 
BMI, self-reported HTN, 
family HTN, blood lead; 
also stratified by serum 
creatinine
HTN = SBP ≥ 140 or 
DBP ≥ 90 or self-
report; SBP, DBP; 
MBP = DBP + pulse 
pressure/3
BCd T2 + SBP
BCd T3 + SBP
BCd T3 + DBP
BCd T3 + MBP
BCd T3 + HTN
Effect of BCd on BP 
strengthened with 
renal dysfunction
Cross-sectional 
(KHANES 2005):
1. B
2. A/B
3. B/C
4. B
Eum et al. 
2008
Men 55–75 years of age from 
Rome, Italy; excluded treated HTN 
subjects; n = 1,223; mean BCd, 
0.62 μg/L
BCd Age, alcohol consumption, 
number of cigarettes/day, 
BMI, HDL cholesterol, 
non-HDL cholesterol, 
serum lead, heart rate, 
driving min/day, skin-fold 
thickness
SBP, DBP; MBP = DBP 
+ 1/3(SBP − DBP)
BCd o SBP
BCd o DBP
BCd o MBP
Cross-sectional 
(New Risk Factors 
Project, June 1989 to 
December 1990):
1. B
2. B
3. A/B
4. B
Menditto 
et al. 1998
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SDs: UCd, men, 1.8 × 2.5 = 4.5 μg/g; UCd, 
women, 2.4 × 2.8 = 6.72 μg/g; BCd, men, 
2.2 × 1.9 = 4.18 μg/L; BCd, women, 
2.3 × 1.8 = 4.14 μg/L (Kurihara et al. 2004); 
and continuous log-transformed BCd 
(Menditto et al. 1998). Kurihara et al. (2004) 
used multivariable analysis to control for 
smoking status but did not separate former 
smokers from nonsmokers. Eum et al. (2008) 
controlled for former, current, and never-
smokers, and Menditto et al. (1998) controlled 
for number of cigarettes smoked per day. Each 
of these studies statistically adjusted for smok-
ers and nonsmokers but did not present the 
results separately for these two groups. Eum 
et al. (2008) ran separate regression models 
for low (< 0.95 mg/dL), medium (≥ 0.95 and 
< 1.05 mg/dL), and high (≥ 1.05 mg/dL) 
serum creatinine to adjust for renal dysfunc-
tion, and Kurihara et al. (2004) adjusted for 
β-2-microglobulin, which is a measure of tubu-
lar renal dysfunction. The study conducted by 
Menditto et al. (1998) was unique among this 
group of studies because they excluded treated 
hypertensive subjects; however, they did not 
report measures of association.
Small studies, not limited to nonsmokers. 
These studies ranged in sample size from 154 
to 692 subjects. Outcome measures included 
SBP and DBP (Schutte et al. 2008; Staessen 
et al. 2000; Telisman et al. 2001) and 24-hr 
ambulatory SBP and DBP (Staessen et al. 
2000). Exposure measures included 24-hr 
log-transformed UCd (Schutte et al. 2008; 
Staessen et al. 2000) and log-transformed 
BCd (Schutte et al. 2008; Staessen et al. 
2000; Telisman et al. 2001). Staessen et al. 
(2000) conducted a combined cross-sectional 
and prospective study of 692 residents of two 
rural areas in Belgium, one with known envi-
ronmental exposures to cadmium from zinc 
smelters. The study period included the years 
1985–1989 and 1991–1995 for the same par-
ticipants (less those lost to follow-up) after 
interventions to reduce cadmium exposure. 
The Schutte et al. (2008) analysis evaluated 
cross-sectional data from a sample of 557 sub-
jects from this same study restricted to the 
years 1991–1994 and included 26 occupa-
tionally exposed men. A case–control study 
(Telisman et al. 2001) restricted participants 
to 154 nonoccupationally exposed men; 
however, measures of association were not 
  presented.
Comparison of multivariate adjusted esti-
mated effects. Results from eight studies pro-
vided adequate data to compare estimated 
effects. Results from five studies provided 
sufficient data for meta-analysis, using three 
studies for each analysis, with one study used 
in two meta-analyses of different exposures.
BCd and HTN. Figure 1 presents the esti-
mated dose–response effects of BCd on HTN. 
In multivariable analysis that adjusted for 
smoking status and use of anti-HTN medi-
cations, Tellez-Plaza et al. (2008) estimated 
associations between HTN and BCd levels 
categorized by quartiles, with the first quartile 
used as the reference group (BCd ≤ 0.20 μg/L); 
quartile 2 = 0.20–0.40 μg/L; quartile 3 = 
0.40–0.70 μg/L; and quartile 4 = > 0.70 μg/L. 
Relative to the first quartile (819 cases and 
1,689 noncases), subjects in the third quartile 
(1,452 cases and 1,369 noncases) were 25% 
more likely to be hypertensive [odds ratio 
(OR) = 1.25; 95% CI, 0.87–1.81], but HTN 
was not associated with exposures in the sec-
ond and fourth quartiles. Additionally, the 
authors compared the 90th and 10th percen-
tiles in never-smokers (n = 5,486); the non-
significant effect estimate (OR = 1.14; 95% 
CI, 0.89–1.45) was equivalent to that of the 
third quartile. Eum et al. (2008) categorized 
BCd levels into tertiles, with tertile 1 (refer-
ence group) ranging from 0.18 to 1.28 μg/L, 
tertile 2 from 1.29 to 1.86 μg/L, and tertile 
3 from 1.87 to 5.52 μg/L. Subjects in the 
Table 1. continued
Study population
Exposure 
measure Covariates Outcome measure Key findingsa
Study design/ 
WOE codesb Reference
Small studies, not limited to nonsmokers
Men and women ≥ 20 years of age; 
2 rural areas in Belgium, one near 
three zinc smelters; arithmetic mean 
BCd for high and low exposure areas, 
0.98/0.08 μg/L; geometric mean 
24-hr UCd for high and low exposure 
areas, 9.8/7.1 nmol/24-hr urine; 
n = 557, including 41 men and 37 
women smokers, 26 occupationally 
exposed men
BCd, 24-hr UCd Sex, age, BMI, 
γ-glutamyl-transferase, 
blood glucose, 
current smoker versus 
nonsmoker, anti-HTN 
treatment, total 
cholesterol, HDL
SBP, DBP; MBP = 
DBP + 1/3 pulse 
pressure; average 
of five consecutive 
readings
UCd – SBP
BCd o SBP
BCd o DBP
BCd o MBP
Cross-sectional 
(1991–1994):
1. A
2. C
3. B/C
4. B
Schutte 
et al. 2008
Same as above, except included time 
period before interventions to reduce 
exposure levels; baseline geometric 
mean BCd for men and for women, 
1.26/1.23 μg/L; baseline geometric 
mean 24 hr UCd for men and for 
women, 11.8/8.8 nmol/24 hr;  
n = 336 men and 356 women
BCd, 24-hr UCd SBP, DBP; average of five 
consecutive readings; 
time-integrated analysis 
of SBP and DBP 
averaged over fifteen 
readings, 1985–1995; 
24-hr ambulatory BP
Age at baseline, 
change in BMI, 
γ-glutamyl- 
transferase, urinary 
Na:K, anti-HTN 
drugs, smoking 
(no change, quit, 
acquired), oral 
contraceptive use
BCd – DBP among men 
never on anti-HTN 
drugs
BCd + SBP, DBP among 
premenopausal 
women
Longitudinal BCd + DBP 
among women
UCd – SBP, DBP among 
men never on anti-
HTN drugs
UCd – 24 hr SBP among 
perimenopausal and 
postmenopausal 
women
Cross-sectional 
(CadmiBel 1985–
1989 and Prospective 
PheeCad compared 
1991–1995 with 
1985–1989):
1. A
2. C
3. B/C
4. B
Staessen 
et al. 2000
Croatian men 20–54 years of age, 
andrology clinic; excluded occu-
pationally exposed, HTN-treated 
subjects, renal or other disease 
that could affect BP; median BCd, 
0.83 μg/L; n = 154
BCd SBP, DBP BMI, blood lead, 
alcohol, blood cop-
per, smoking
BCd o SBP
BCd o DBP
Case–control:
1. B
2. C
3. B
4. B
Telisman 
et al. 2001
Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; KHANES, Korean National Health and Nutrition Examination Survey; MBP, mean blood pressure; nM/3, 
nanomolar/3-hr urine; NHANES, National Health and Nutrition Examination Survey; T, tertile. 
aKey findings: +, significant positive association; –, significant inverse association; o, null association. bWOE codes: 1, association; 2, environmental equivalence; 3, population equiva-
lence; 4, bias.Gallagher and Meliker
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highest tertile were 52% more likely to have 
HTN than were those in the lowest tertile of 
BCd (OR = 1.52; 95% CI, 1.13–2.05).
BCd, and SBP and DBP. Figure 2 shows 
the relationships between BCd and SBP and 
DBP in men and women separately. Tellez-
Plaza et al. (2008) reported that, in men, 
BCd (nmol/L) in the 90th relative to the 10th 
percentile was significantly associated with 
DBP (β = 1.81 mmHg; 95% CI, 0.40–3.22); 
this relationship, however, was not significant 
for SBP. In contrast, Staessen et al. (2000) 
reported inverse associations of log-  transformed 
BCd (nmol/L) with SBP and DBP among men 
never on anti-HTN medications; however, this 
inverse relationship was only significant for 
DBP (β = –3.10 mmHg; 95% CI, –5.86 to 
–0.34). Because results from a third study were 
not available, meta-analysis was not performed 
using these findings for men.
Results were available from three stud-
ies that evaluated the relation between BCd 
and SBP among women, so we conducted a 
meta-analysis. Statistically significant posi-
tive associations were reported by Pizent et al. 
(2001) for a one-unit increase in untrans-
formed BCd (micrograms per liter) among 
nonsmoking women (β = 3.14 mmHg; 95% 
CI, 0.14–6.14) and by Staessen et al. (2000) 
for a one-unit increase in log transformed 
BCd (nanomoles per liter) among pre-
menopausal women (β = 4.83 mmHg; 95% 
CI, 0.17– 9.49). Tellez-Plaza et al. (2008) also 
reported positive, although insignificant, asso-
ciations between BCd (nanomoles per liter), 
comparing 90th and 10th percentiles and 
SBP among women (β = 1.40 mmHg; 95% 
CI, –0.81 to 3.61). Overall estimated effects 
were significantly positive (β = 2.39 mmHg; 
95% CI, 0.69–4.09; p = 0.006), with mini-
mal heterogeneity (I2 = 3%).
All three studies showed positive relation-
ships between BCd and DBP, with similar 
effect estimates, among women; however, 
only the findings of Staessen et al. (2000) and 
Tellez-Plaza et al. (2008) showed statistical 
significance (respectively: β = 3.84 mmHg; 
95% CI, 0.86–6.82; β = 1.78; 95% CI, 0.64–
2.92). The effect estimate for nonsmoking 
women found by Pizent et al. (2001) was sim-
ilar to that found by Tellez-Plaza et al. (2008) 
for all women (β = 1.40 mmHg; 95% CI, 
–0.15 to 2.95). As in the meta-analysis for 
BCd and SBP, overall associations for BCd 
and DBP were significantly positive (β = 1.84 
mmHg; 95% CI, 0.95–2.74; p < 0.0001), 
with minimal heterogeneity (I2 = 3%).
BCd dose response. In Figure 3, we com-
pared BCd associations with SBP and DBP 
by levels of exposure. Among never-smokers, 
BCd levels in the 90th percentile were sig-
nificantly associated with elevated SBP 
(β = 2.35 mmHg; 95% CI, 0.64–4.05) and 
DBP (β = 3.25 mmHg; 95% CI, 1.69–4.84) 
Figure 2. BCd: SBP and DBP, women and men separately (partial regression coefficients and 95% CIs).
Staessen et al. (2000): BCd (nmol/L) = continuous log-transformed; 95% CI, coefficient ± 1.96 × SE. Pizent 
et al. (2001): BCd (μg/L) = continuous untransformed; 95% CI, coefficient ± 1.96 × SE. Tellez-Plaza et al. 
2008: BCd (nmol/L), 90th to 10th percentile. Size of point estimate symbols varies to identify different 
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Figure 3. BCd dose–response comparisons: SBP and DBP (partial regression coefficients and 95% CIs) Tellez-
Plaza et al. (2008): BCd (μg/L) quartiles: Q1 (reference), ≤ 0.20; Q2, 0.20–0.40; Q3, 0.40–0.70; Q4, ≥ 0.70. Eum et al. 
(2008): BCd (μg/L) tertiles: T1 (reference), 0.18–1.28; T2, 1.29–1.86; T3, 1.87–5.52. All data are for men and women 
combined. Sizes of different point estimate symbols for quartiles and tertiles reflect increasing BCd levels.
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relative to the 10th percentile (Tellez-Plaza 
et al. 2008). In the smoking-adjusted analysis, 
the third quartile of BCd exposure relative 
to the lowest level showed a larger estimated 
effect (SBP: β = 1.85 mmHg; 95% CI, 
0.52–3.19; DBP: β = 2.01 mmHg; 95% CI, 
0.86–3.15) than did the second quartile; how-
ever, for both SBP and DBP, the effect estimate 
for the fourth quartile was attenuated relative 
to that of the third (Tellez-Plaza et al. 2008). 
For SBP, Eum et al. (2008) reported a posi-
tive association with the second tertile of BCd 
compared with the reference group (β = 1.651 
mmHg; 95% CI, 0.099–3.203) and a slightly 
stronger association with BCd exposures in 
the third tertile (β = 2.204 mmHg; 95% CI, 
0.649–3.760) relative to the first quartile. For 
DBP, only the third tertile reached statisti-
cal significance (β = 1.671 mmHg; 95% CI, 
0.626–2.716). Comparisons of second and 
third levels across these two studies of lower 
population mean BCd (0.42 μg/L; Tellez-Plaza 
et al. 2008) and higher population mean BCd 
(1.67 μg/L; Eum et al. 2008) suggest a positive 
dose response.
UCd and HTN. Figure 4 presents study 
findings regarding the association between 
UCd and HTN. Tellez-Plaza et al. (2008) used 
a dichotomous measure of UCd obtained from 
spot urine samples, compared the 90th and 
10th percentiles, and used multivariate adjust-
ment to statistically adjust for urine creatinine; 
in contrast, Kurihara et al. (2004) used an 84% 
cutoff (4.5 μg/g for men and 6.72 μg/g for 
women) and directly adjusted UCd for urine 
creatinine. Whittemore et al. (1991) also meas-
ured cadmium from spot urine samples but 
adjusted for specific gravity. They used anti-
HTN drug use to define HTN, whereas 
Kurihara et al. (2004) used standard BP cutoff 
measures, and Tellez-Plaza et al. (2008) incor-
porated both definitions, as well as self-report 
of a physician diagnosis of HTN. Despite these 
methodological differences, inverse relation-
ships were found between UCd and HTN 
(HTN) among men and among women. 
ORs varied considerably across studies, with 
ORs of 0.62 for men and 0.67 for women in 
the Kurihara et al. (2004) study, and ORs of 
0.34 and 0.94 for never-smoking men and 
women in the Tellez-Plaza et al. (2008) and 
Whittemore et al. (1991) studies, respectively. 
Meta-analysis of results from these three stud-
ies showed UCd to be significantly negatively 
associated with HTN (OR = 0.65; 95% CI, 
0.45–0.94; p = 0.02); however, heterogeneity 
was substantial (I2 = 83%).
UCd, and SBP and DBP. Figure 5 pres-
ents partial regression coefficients (adjusted for 
covariates in multivariable analysis) and 95% 
CIs for the relationship of UCd with SBP and 
DBP, evaluated separately for women and men. 
Statistically significant inverse relationships for 
a one-unit increase in log-  transformed 24-hr 
UCd (nanomoles/liter) with SBP (β = –5.55 
mmHg; 95% CI, –11.04 to –0.06) and 
DBP (β = –4.80 mmHg; 95% CI, –8.19 to 
–1.41) were reported for men who were never 
on anti-HTN drugs (Staessen et al. 2000). 
Although Whittemore et al. (1991) reported 
positive relationships of untransformed UCd 
(μg/L) with SBP and DBP among both nev-
er-smoking men and women, associations 
were not statistically significant. Satarug et al. 
(2005) observed a statistically significant posi-
tive relationship of log-transformed 3-hr UCd 
(nanomolar) with SBP (β = 0.31 mmHg; 95% 
CI, 0.05–0.57) among nonsmoking men who 
were not on anti-HTN medications; how-
ever, the estimated effect size was small, and 
findings were null for women. Overall, these 
results are inconsistent, which may be attrib-
utable, in part, to different units of exposure 
measures, variations in sample sizes, and dif-
ferences in smoking status and anti-HTN 
drug use.
Discussion
Synthesis of findings using a causal inference 
framework. Causal inference criteria provide 
a framework useful to interpret the strength 
and limitations of the evidence regarding an 
association between BCd and/or UCd with 
BP. Hill (1965) and contemporaries (Kundi 
2006; Rothman and Poole 2007) caution 
against using epidemiological causal inference 
criteria as a checklist. Noting these caution-
ary concerns, it is informative to qualitatively 
group these criteria as follows: strength of 
association, consistency among studies, and 
temporality; and dose response, epidemiologi-
cal coherence, and biological plausibility.
Strength of association, consistency, and 
temporality. Positive associations between 
BCd with elevated SBP and DBP were found 
among nonsmokers (Pizent et al. 2001) and 
never-smokers (Tellez-Plaza et al. 2008). 
Statistically significant relationships between 
BCd, SBP and DBP among nonsmokers 
Figure 5. UCd: SBP and DBP, women and men separately (partial regression coefficients and 95% CIs). 
Whittemore et al. (1991): spot UCd (μg/L) adjusted for specific gravity, untransformed; 95% CI visually esti-
mated from published graphs. Staessen et al. (2000): 24-hr UCd (nmol) log transformed; 95% CIs calculated 
as 1.96*SE. Satarug et al. (2005): 3-hr UCd (nanograms) log transformed; 95% CIs estimated from coef-
ficient and t-value. Size of different point estimates varies to identify different studies without quantitative 
or qualitative ranking.
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and never-smokers are interpreted as provid-
ing stronger evidence than associations from 
smoking-adjusted studies because the effects 
of current and ever-smoking, respectively, 
are removed rather than statistically adjusted 
for. Meta-analysis supported strength of asso-
ciation, and the relationship between BCd 
and BP was evident across three studies of 
women (Pizent et al. 2001; Staessen et al. 
2000; Tellez-Plaza et al. 2008), regardless of 
smoking adjustment or stratification meth-
ods. In the only prospective study, Staessen 
et al. (2000) found that BCd was positively 
related to SBP and DBP in premenopausal 
women. Moreover, a longitudinal decrease in 
BCd was documented after environmental 
remediation, and decreased BCd was associ-
ated with decreased DBP in women (Staessen 
et al. 2000). Because BCd is more influenced 
by recent exposure, and SBP and DBP are 
concurrent measures, the evidence suggests 
a temporal relationship between BCd and 
recent effects. BCd may also reflect accumula-
tion of cadmium with age; however, all studies 
adjusted for or matched on age.
BCd was less consistently associated with 
HTN. This may be due to the disparate defi-
nitions of HTN. Studies similar in terms of 
adjustment for measures of renal dysfunction 
and populations with relatively high BCd lev-
els reported discrepant findings; specifically, 
Eum et al. (2008) reported positive associa-
tions between BCd, and BP and HTN in a 
sample with a geometric mean > 2.0 μg/L, 
whereas Kurihara et al. (2004) reported no 
association between BCd and HTN in a sam-
ple with similarly high BCd (1.67 μg/L). BCd 
means for both of these samples were greater 
than that of the NHANES sample (0.42 μg/L) 
(Tellez-Plaza et al. 2008), and BCd was posi-
tively associated with BP in this low-exposure 
population, as well as in the Eum et al. (2008) 
study of a high-exposure population. Thus, the 
results of the present review do not support 
Nakagawa and Nishijo’s (1996) conclusions 
that general populations with low exposures 
show positive associations between cadmium 
and BP, whereas populations with kidney 
dysfunction and high exposures show inverse 
associations. Of note, the only study reviewed 
in both the present and original review was 
the Staessen et al. (2000) study; however, 
Nakagawa and Nishijo (1996) referenced ear-
lier versions (Staessen et al. 1984, 1991) and 
thus did not include the more recent findings 
of a positive association between BCd and BP 
in women (Staessen et al. 2000).
Several studies showed an inverse associa-
tion between UCd, a biomarker of long-term 
exposure, and HTN. This inverse relationship 
was evident in both high- and low-exposure 
populations, so again, this does not support 
the earlier systematic review’s interpretation 
that inverse associations between cadmium 
and BP are characteristic of populations 
with higher exposures and associated renal 
dysfunction (Nakagawa and Nishijo 1996). 
Specifically, both the Tellez-Plaza et al. (2008) 
study of a low-exposure population (mean 
BCd = 0.42 μg/L; mean UCd = 0.28 μg/L) 
and the Kurihara et al. (2004) study of a high-
exposure population (BCd geometric mean, 
2.2–2.3 μg/L; UCd geometric mean 1.8–2.4 
μg/g creatinine) found statistically significant 
inverse relationships between UCd and HTN. 
Staessen et al. (2000) evaluated SBP and 
DBP averaged over 15 readings taken during 
the period 1985–1995; this time-integrated 
analysis also showed an inverse relationship 
between UCd and long-term DBP in men.
A limitation common to all studies, and 
thus to the meta-analysis of the relation 
between UCd and HTN, is that the outcome 
of HTN was not consistently defined across 
studies. Although meta-analysis findings sup-
port an inverse relationship, the finding of 
substantial heterogeneity might reflect out-
come misclassification. Thus, although causal 
inference criteria support the interpretation of 
a positive association between BCd and higher 
SBP and DBP, the relationship between UCd, 
and BP and HTN remains uncertain.
Dose response, epidemiologic coher-
ence, and biologic plausibility. Dose–response 
analyses of BCd tertiles and quartiles were not 
restricted to never-smokers, so interpretations 
regarding cadmium’s exposure–response effects 
independent of smoking are limited. It is nota-
ble in the Tellez-Plaza et al. (2008) study, how-
ever, that for the outcomes of SBP and DBP, 
never-smokers show the largest effect estimates 
when comparing the 90th and 10th percentiles 
of BCd exposures and that, in the smoking-
adjusted analysis of dose response in this same 
study, the fourth quartile of cadmium expo-
sure shows a smaller effect estimate compared 
with the third quartile. Some studies show that 
smokers have lower BP than do non  smokers 
(Green et al. 1986; Primatesta et al. 2001; 
Stolarz et al. 2003), and Lee (2008) found that 
smoking was a risk factor for masked HTN, 
that is, normal clinic BP but elevated ambula-
tory BP, suggesting that effect estimates in the 
upper range of cadmium exposure may be con-
founded by cigarette smoking. This hypothesis 
warrants investigation.
Based upon animal and in vitro studies, 
cadmium may increase BP through vascular 
effects. A hypothesized mechanism of action 
(MOA) for cadmium in humans is inhibition 
of endothelial nitric oxide synthase protein in 
blood vessels, which suppresses acetylcholine-
induced vascular relaxation to induce HTN 
(Yoopan et al. 2008). On the other hand, 
serum cotinine, a metabolite of nicotine, 
has been inversely related to BP in smokers 
(Benowitz and Sharp 1989), and Ghasemi 
et al. (2010) reported a significantly positive 
correlation between serum nitric oxide and 
the number of cigarettes smoked per day, sug-
gesting a possible MOA for how smoking 
might confound the relationship between 
cadmium and BP.
The inverse relationships observed between 
UCd and BP raise the question of whether 
cadmium might have depressor effects. 
Experimental findings suggest that cadmium 
binds to calcium-binding sites on the regula-
tory protein calmodulin, and like calcium, 
cadmium can increase dopamine synthesis in 
the brain that lowers BP (Sutoo and Akiyama 
2000). Further research is merited to investi-
gate this hypothesized MOA in humans.
HTN is a disease of differential physio-
logi  cal characterization. Approximately one-
fourth of HTN subjects, particularly those 
with renovascular HTN, show high levels 
of angiotensin II, a vasoconstrictor (Malpas 
2010). Angiotensin II receptor binding sites 
are located in the brain at sites involved with 
sympathetic nerve activity via baro  reflex 
regulation (Malpas 2010). Puri and Saha 
(2003) found that in rats cadmium inhib-
ited angiotensin-converting enzyme (ACE) 
at low, medium, and high doses without a 
dose–  response effect yet paradoxically induced 
HTN; they postulated that cadmium’s vascu-
lar effects predominated over its central effects 
in HTN rats. Although cadmium’s central ver-
sus vascular effects in humans are unknown, it 
has been shown that the ACE inhibitor val-
sartan is more effective in preventing cardiac 
failure in HTN men than in HTN women 
(Zanchetti et al. 2006). In light of meta-
analysis findings of an association between 
BCd and elevated BP in women, perhaps 
future research into cadmium’s mechanisms of 
action may lead to improved   gender-specific 
  therapeutic interventions.
Staessen et al. (2000) found an inverse 
association between BCd and BP in men never 
on anti-HTN drugs. This finding and the 
meta-analysis finding of UCd’s inverse asso-
ciation with HTN, yet UCd’s positive asso-
ciations with heart failure (Peters et al. 2010), 
seem counterintuitive, because HTN is an 
established risk factor for cardiovascular dis-
ease. In as many as 33% of HTN heart disease 
patients, however, heart failure is unrecognized 
because as this condition develops, the left 
ventricle becomes too weak to raise DBP (Riaz 
2010). Further, masked HTN is prevalent in 
10–20% of the adult population (O’Brien 
2008). The extent to which undiagnosed and 
untreated HTN disease is associated with cad-
mium exposure has not been evaluated.
Methodological critique of individual stud-
ies. Cross-sectional analysis and inadequate 
specification of the duration of HTN limit 
temporal interpretations. Misclassification bias 
may result from the inconsistent measurement 
of HTN across studies. Even the measurement Cadmium, blood pressure, and hypertension: a review
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of BP may be biased by the phenomenon of 
masked HTN, which has been associated with 
cardiac and arterial target organ damage com-
parable with that of sustained HTN (Kotsis 
et al. 2008). Hypertensive heart failure is of 
even greater prevalence (Riaz 2010), and thus, 
nonmeasurement may be an additional source 
of outcome misclassification.
Sample selection considerations and expo-
sure measurement error are additional limita-
tions in these studies. Staessen et al. (2000) 
included men with known occupational expo-
sures, as did Schutte et al. (2008), thus limit-
ing interpretations of findings in men. Further, 
industrial exposures to cadmium emissions 
may have uniquely influenced dietary cad-
mium intake for subjects who consumed food 
grown in cadmium-contaminated soil. Of 
the six studies that separated smokers from 
nonsmokers, the four smaller studies used 
specific samples that limited generalizability 
of findings, and the Whittemore et al. (1991) 
study was not a probability sample. Treated 
HTN subjects were either analyzed separately 
or excluded in all smoking-stratified studies 
except the Tellez-Plaza et al. (2008) study. 
Further, the use of spot urine samples in the 
Tellez-Plaza et al. (2008), Whittemore et al. 
(1991), Vivoli et al. (1989), and Kurihara 
et al. (2004) studies may limit the accuracy 
of exposure assessment due to variable uri-
nary dilution effects throughout the day (Barr 
et al. 2005). Urine specific gravity and crea-
tinine correction were used to address this 
limitation, however, and Berlin et al. (1985) 
reported a correlation between cadmium lev-
els measured in spot and 24-hr samples from 
occupationally exposed subjects.
Limitations of meta-analysis. The small 
number of studies precluded quantitative bias 
assessment, as well as meta-analysis of the 
relation between BCd with SBP and DBP 
among men. Further, Menditto et al. (1998) 
and Kurihara et al. (2004) did not report sta-
tistics for null findings regarding the relation 
between BCd and BP, so meta-analysis may 
be subject to positive reporting bias. On the 
other hand, Lin et al. (1995) and Vivoli et al. 
(1989) found positive relationships between 
BCd and BP but did not report comparable 
measures of association, which may have sub-
jected the meta-analysis to negative reporting 
bias. Meta-analysis of SBP and DBP used 
both continuous (Pizent et al. 2001; Staessen 
et al. 2000) and 90:10th percentile exposure 
measures (Tellez-Plaza et al. 2008). Similarly, 
meta-analysis of HTN used both continu-
ous (Whittemore et al. 1991) and high:low 
UCd exposure measures (Kurihara et al. 
2004; Tellez-Plaza et al. 2008). Further, units 
of measure varied across studies. Thus, there 
were substantial differences in exposure meas-
ures that limited interstudy comparisons of 
effect estimates.
Conclusion and 
Recommendations
The body of evidence relating BCd to BP 
suggests a positive relationship, especially in 
females, but in the absence of dose–response 
gradients in never-smokers is inconclusive. 
The inverse relationships between UCd and 
BP reported in the meta-analysis lack strong 
mechanistic support. Our findings offer new 
insights, however, because these paradoxical 
relationships were evident in both high- and 
low-exposure populations, as indicated by 
mean population cadmium exposure levels, 
and thus contradict earlier assumptions that 
this inverse association only reflected higher 
cadmium exposures. In light of this review’s 
evidence of an association between BCd and 
higher BP, an established risk factor for car-
diovascular disease, and recent evidence of a 
prospective association between long-term 
cadmium exposure and cardiovascular mor-
tality (Menke et al. 2009), cadmium merits 
further epidemiologic inquiry. The European 
Food Safety Authority (2009) recognized 
that cadmium has been associated with myo-
cardial infarction (Everett and Frithsen 2008) 
and alterations in cardiovascular function 
(Schutte et al. 2008). More rigorous investiga-
tion of both short- and longer-term effects of 
nonsmoking cadmium exposures may shed 
insights regarding susceptibility to HTN and 
cardiovascular disease by identifying cadmium 
dose–response relationships over time.
This line of research would benefit from 
both physiological studies of cadmium’s 
MOA, and longitudinal epidemiological stud-
ies of never-smoking, general populations 
(i.e., non-occupationally and nonindustrially 
exposed) to evaluate the relationships among 
BCd and UCd, and SBP, DBP, and sustained 
HTN. Sufficient power would be needed to 
examine effects in the never-smoking general 
population, with subset analyses by gender,
A longitudinal study would help tease out 
temporally relevant influences, such as meno-
pausal status and hormonal effects. Cadmium 
has been shown to suppress progesterone 
production (Paksy et al. 1997) and has also 
been associated with increased serum levels of 
follicle-stimulating hormone (Gallagher et al. 
2010). Insights regarding gender differences in 
cadmium toxicokinetics may be gained by mea-
suring iron levels, because iron competes with 
cadmium for binding sites on the metal trans-
porter divalent metal transporter 1 (DMT1) 
(Nishijo et al. 2004). Because cadmium has 
been associated with peripheral arterial disease 
(PAD) (Navas-Acien et al. 2004), and zinc and 
UCd were inversely associated in patients with 
PAD (Tsai et al. 2004), zinc intake also merits 
consideration. Further, Guallar et al. (2006) 
found that BCd partially explained the rela-
tionship between elevated homocysteine levels 
and PAD. Methylenetetrahydrofolate reductase 
(MTHFR) is a key enzyme in homocysteine 
metabolism, and MTHFR gene polymor-
phisms were associated with essential HTN 
(Ilhan et al. 2008).
An increasing body of evidence suggests 
that cadmium is a risk factor for cardiovas-
cular morbidity and mortality, as well as a 
contaminant of concern in our food sup-
ply (European Food Safety Authority 2009; 
Reuben 2010). Findings from this meta-anal-
ysis indicate a positive association between 
BCd and increased BP, particularly in women, 
and identify gaps in research regarding the 
association of cadmium exposure with HTN. 
Longitudinal studies are merited to evaluate 
the relationships of cadmium exposures with 
more rigorous measures of HTN; physiologi-
cal indicators of cadmium’s central, cardiac, 
and vascular effects; hormonal nutritional 
factors; genetic susceptibilities; and cardio-
vascular disease among never-smokers.
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